Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants

R. Koya, J. Andersen, H. Fernandez, Mark Goodman, N. Spector, R. Smith, J. Hanlon, P. A. Cassileth

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We conducted a retrospective review of 125 patients undergoing high-dose therapy and stem cell rescue in order to evaluate the incidence of documented infection and the utility of the administration of vancomycin empirically. All patients received prophylactic oral quinolone therapy. Because neutropenia in this setting is relatively brief, 21 patients never manifested fever, and no patient died of infection. Of the remaining 104 patients, positive blood cultures were obtained in only 10, nine with a gram stain positive and one with a gram stain negative organism. Sixty-two patients without any evidence of gram positive infection received vancomycin according to the existing algorithm for care of neutropenic fevers. In this population of patients, empiric administration of vancomycin for neutropenic fevers without culture documentation appears to be unnecessary, could be discontinued safely and at substantial cost savings, and might slow the appearance of vancomycin-resistant organisms.

Original languageEnglish
Pages (from-to)923-926
Number of pages4
JournalBone Marrow Transplantation
Volume21
Issue number9
StatePublished - May 1 1998

Fingerprint

Febrile Neutropenia
Vancomycin
Transplants
Fever
Infection
Cost Savings
Quinolones
Peripheral Blood Stem Cells
Neutropenia
Documentation
Stem Cells
Incidence
Therapeutics
Population

Keywords

  • Autologous stem cell transplant
  • Infections
  • Neutropenic fever
  • Vancomycin

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. / Koya, R.; Andersen, J.; Fernandez, H.; Goodman, Mark; Spector, N.; Smith, R.; Hanlon, J.; Cassileth, P. A.

In: Bone Marrow Transplantation, Vol. 21, No. 9, 01.05.1998, p. 923-926.

Research output: Contribution to journalArticle

Koya, R, Andersen, J, Fernandez, H, Goodman, M, Spector, N, Smith, R, Hanlon, J & Cassileth, PA 1998, 'Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants', Bone Marrow Transplantation, vol. 21, no. 9, pp. 923-926.
Koya, R. ; Andersen, J. ; Fernandez, H. ; Goodman, Mark ; Spector, N. ; Smith, R. ; Hanlon, J. ; Cassileth, P. A. / Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. In: Bone Marrow Transplantation. 1998 ; Vol. 21, No. 9. pp. 923-926.
@article{c92c7f5d0083461fb607f8dc3cf47a96,
title = "Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants",
abstract = "We conducted a retrospective review of 125 patients undergoing high-dose therapy and stem cell rescue in order to evaluate the incidence of documented infection and the utility of the administration of vancomycin empirically. All patients received prophylactic oral quinolone therapy. Because neutropenia in this setting is relatively brief, 21 patients never manifested fever, and no patient died of infection. Of the remaining 104 patients, positive blood cultures were obtained in only 10, nine with a gram stain positive and one with a gram stain negative organism. Sixty-two patients without any evidence of gram positive infection received vancomycin according to the existing algorithm for care of neutropenic fevers. In this population of patients, empiric administration of vancomycin for neutropenic fevers without culture documentation appears to be unnecessary, could be discontinued safely and at substantial cost savings, and might slow the appearance of vancomycin-resistant organisms.",
keywords = "Autologous stem cell transplant, Infections, Neutropenic fever, Vancomycin",
author = "R. Koya and J. Andersen and H. Fernandez and Mark Goodman and N. Spector and R. Smith and J. Hanlon and Cassileth, {P. A.}",
year = "1998",
month = "5",
day = "1",
language = "English",
volume = "21",
pages = "923--926",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants

AU - Koya, R.

AU - Andersen, J.

AU - Fernandez, H.

AU - Goodman, Mark

AU - Spector, N.

AU - Smith, R.

AU - Hanlon, J.

AU - Cassileth, P. A.

PY - 1998/5/1

Y1 - 1998/5/1

N2 - We conducted a retrospective review of 125 patients undergoing high-dose therapy and stem cell rescue in order to evaluate the incidence of documented infection and the utility of the administration of vancomycin empirically. All patients received prophylactic oral quinolone therapy. Because neutropenia in this setting is relatively brief, 21 patients never manifested fever, and no patient died of infection. Of the remaining 104 patients, positive blood cultures were obtained in only 10, nine with a gram stain positive and one with a gram stain negative organism. Sixty-two patients without any evidence of gram positive infection received vancomycin according to the existing algorithm for care of neutropenic fevers. In this population of patients, empiric administration of vancomycin for neutropenic fevers without culture documentation appears to be unnecessary, could be discontinued safely and at substantial cost savings, and might slow the appearance of vancomycin-resistant organisms.

AB - We conducted a retrospective review of 125 patients undergoing high-dose therapy and stem cell rescue in order to evaluate the incidence of documented infection and the utility of the administration of vancomycin empirically. All patients received prophylactic oral quinolone therapy. Because neutropenia in this setting is relatively brief, 21 patients never manifested fever, and no patient died of infection. Of the remaining 104 patients, positive blood cultures were obtained in only 10, nine with a gram stain positive and one with a gram stain negative organism. Sixty-two patients without any evidence of gram positive infection received vancomycin according to the existing algorithm for care of neutropenic fevers. In this population of patients, empiric administration of vancomycin for neutropenic fevers without culture documentation appears to be unnecessary, could be discontinued safely and at substantial cost savings, and might slow the appearance of vancomycin-resistant organisms.

KW - Autologous stem cell transplant

KW - Infections

KW - Neutropenic fever

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=0031953003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031953003&partnerID=8YFLogxK

M3 - Article

C2 - 9613785

AN - SCOPUS:0031953003

VL - 21

SP - 923

EP - 926

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -